Injectable drug to ease advanced Parkinson's disease symptoms approved by FDA
The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in study participants.
Continuous Parkinson's Disease Therapy Wins FDA Nod
"For too long, the Parkinson's community has had limited treatment options for advanced disease," Robert Hauser, MD, MBA, of the University of South Florida in Tampa, said in an A
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor fluctuations in adults with advanced Parkinson’s disease (PD). The approval was supported by the pivotal 12-week Phase 3 study evaluating the efficacy of continuous subcutaneous infusion of Vyalev in adult patients with advanced PD compared to oral immediate-release carbidopa/levodopa (CD/LD IR),
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson’s disease.
After rejections, AbbVie secures approval for Parkinson’s drug
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
FDA Approves AbbVie's Parkinson's Disease Drug Vyalev
Thursday said that the U.S. Food and Drug Administration (FDA) has approved Vyalev for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). The approval was supported by the pivotal phase 3 study evaluating Vyalev in adults with advanced PD compared to carbidopa/levodopa,
AbbVie Gets FDA OK for Vyalev in Adults With Advanced Parkinson's Disease
AbbVie has finally won Food and Drug Administration approval of its Vyalev therapy for patients with advanced Parkinson's disease. AbbVie on Thursday said the FDA green light makes Vyalev the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with the neurodegenerative condition.
Man’s simple act of kindness meant the world to woman with Parkinson’s disease
"It's the little things in life that really matter," Liz Marshall told News 4, after nominating the driver of a Waste ...
Carteret County gym fighting Parkinson’s with boxing
Performance Zone, a gym in Morehead City, offers a program aimed at improving the lives of individuals battling Parkinson's ...
Research reveals an intricate gut-brain connection to Parkinson’s Disease
Recent research suggests a gut-brain connection in Parkinson’s Disease, impacting diagnosis, progression, and treatment ...
Crain's Chicago Business10h
New AbbVie Parkinson’s drug finally gets green light to hit U.S. market
After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...
University of Dundee18h
Dundee scientists to lead new global Parkinson’s disease initiative
The Michael J. Fox Foundation (MJFF) has launched a major new initiative to rapidly expedite development of therapeutic ...
Video shows remarkable improvements for Parkinson's patient after new infusion drug
A patient who received a new infusion therapy treatment for Parkinson’s disease showed progress after just two days, Sherwood Forest Hospitals said.
For people with Parkinson's, moving is a mental challenge as well as a physical one
It's well known that Parkinson's disease can impair a person's ability to perform movements like grabbing a coffee cup, with ...
Zacks.com on MSN1d
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) ...